EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies

Javier Muñoz, Shayna Sarosiek, Jorge J Castillo iD

The Oncologist · 2023

DOI: 10.1093/oncolo/oyac260 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Oncologist, 2023. Verfasst von Javier Muñoz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell, Lymphoma, B-Cell. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BeiGene USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ibrutinib is a first-generation inhibitor of Bruton tyrosine kinase (BTK) that is currently approved to treat patients with B-cell malignancies, including Waldenström macroglobulinemia (WM), relapsed/refractory (R/R) mantle cell lymphoma (MCL), R/R marginal zone lymphoma (MZL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Off-target adverse effects, such as atrial fibrillation, hypertension, and bleeding, have been observed and may limit a patient’s tolerance for treatment. Currently, there is no well-established treatment regimen for patients who cannot tolerate ibrutinib. Approaches to address such patients include managing ibrutinib side effects with supportive care or dose reductions, switching to an alternative covalent BTK inhibitor, or abandoning covalent BTK inhibitors for alternative forms of treatment. Here we review the literature and provide guidance on treating ibrutinib-intolerant patients with B-cell malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-CellLymphoma, B-CellHumansAdultProtein Kinase InhibitorsB-LymphocytesAdeninePiperidines

Stichwörter der Autor:innen

Bruton’s tyrosine kinaseWaldenström macroglobulinemiachronic lymphocytic leukemiamantle cell lymphomamarginal zone lymphoma

Substanzen

Protein Kinase InhibitorsibrutinibAdeninePiperidines

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
  • Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

ORCID-Profile: Jorge J Castillo

Förderung

  • BeiGene USA

Zitieren

APA

Muñoz, J., Sarosiek, S., & Castillo, J. J. (2023). Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies. The Oncologist. https://doi.org/10.1093/oncolo/oyac260

Vancouver

Muñoz J, Sarosiek S, Castillo JJ. Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies. The Oncologist. 2023. doi:10.1093/oncolo/oyac260

BibTeX
@article{Muoz2023,
  author = {Muñoz, Javier and Sarosiek, Shayna and Castillo, Jorge J},
  title = {Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyac260}
}
Kostenlos starten →